Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SX-682 · 1 trial · 2 indications
Maximum tolerable dose is defined by less than or equal to 30% dose limiting toxicity (DLT) event rate within a given dose combination,
| Arm | Type | Description |
|---|---|---|
| Experimental: SX-682 and Nivolumab | EXPERIMENTAL | SX-682 Dose: 25, 50, 100, 200, 400mg BID taken as an oral pill Nivolumab Dose: 240mg, every 2 weeks via intravenous infusion |
| Name | Type | Description |
|---|---|---|
| SX-682 | DRUG | Allosteric inhibitor to human CXCR1 and CXCR2 receptor |
| Nivolumab Injectable Product | DRUG | humanized monoclonal antibody to program cell death receptor 1 (PD1) |
Inclusion Criteria: Written Informed Consent and HIPAA Authorization 1. Subjects must have the nature of the study explained to them 2. Subjects must be willing and able to comply with scheduled visits, treatment schedule, laboratory tests, pharmacokinetic collections, study biopsies and other req...
SX-682 is an investigational small molecule being studied for the treatment of pancreatic ductal adenocarcinoma (PDAC), a type of pancreatic cancer. It is currently in Phase 1 clinical development as a maintenance therapy in patients with metastatic PDAC.
SX-682 is a small molecule that targets the chemokine receptors CXCR1 and CXCR2. By inhibiting these receptors, it may modulate the tumor microenvironment and enhance the anti-tumor immune response, which is why it is being studied in combination with an immunotherapy agent.
SX-682 is being developed by Bristol-Myers Squibb Company, a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol BMY. The company is conducting clinical trials to evaluate the safety and tolerability of SX-682 in patients with pancreatic cancer.
SX-682 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being tested in clinical trials to assess its safety, tolerability, and potential efficacy in patients with metastatic pancreatic ductal adenocarcinoma.
SX-682 is being studied in a Phase 1 clinical trial with the identifier NCT04477343. This trial evaluates SX-682 in combination with nivolumab as maintenance therapy in patients with metastatic pancreatic ductal adenocarcinoma. The study is active but not recruiting, with an enrollment of 20 participants in the United States.
SX-682 is a distinct investigational small molecule and is not known to be the same as any other approved drug. It is being studied under its own name in clinical trials, and no alternative names have been reported for this compound.